Market Access & Reimbursement
Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
Latest From Market Access
Agency hears from experts on whether PBMs and group purchasing organizations operate under misaligned incentives.
Innovative trial designs add a new layer of uncertainty for health technology appraisal bodies. They are likely to adapt to a changing environment, but there could be a price for companies.
Outcomes-based managed entry agreements designed to help ensure access to expensive new medicines are not sustainable and have so far failed to provide a solution to the problem of funding costly innovative drugs, according to Ad Schuurman from ZIN, the Dutch National Healthcare Institute.
Medicare Part D proposed rule would lower cost sharing for biosimilars to the level of generics for some beneficiaries, allow immediate generic substitution for plans.
CMS outlines possible approach to point-of-sale rebates in Medicare Part D, recognizing that using rebates to lower cost sharing for 'many' would increase premiums for all.
It took NICE, England’s health technology appraisal body, 84 days to say yes to Novartis’ Kisqali and almost a year to recommend Pfizer’s Ibrance. Willingness to sacrifice on price could have had a big impact on timelines.
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
Please Note: Only individuals with an active subscription will be able to access the full article. All other readers will be directed to the abstract and would need to subscribe.